Literature DB >> 19709517

Acute myocardial infarction hospitalization statistics: apparent decline accompanying an increase in smoke-free areas.

Joan R Villalbí1, Antonia Castillo, Montse Cleries, Esteve Saltó, Emília Sánchez, Rosa Martínez, Ricard Tresserras, Emili Vela.   

Abstract

Recent research suggests that the introduction of antismoking regulations reduces the incidence of acute myocardial infarction (AMI). The aim of this study was to analyze changes in AMIs in the Barcelona metropolitan area in Spain following implementation of the 2006 antismoking law. Data was collected on all discharges from hospitals funded by the Catalan Health Service in 2004-2006. All patients aged over 24 years who lived in the area and who received a primary diagnosis of AMI were included. Annual AMI hospitalization rates, with 95% confidence intervals, were estimated for each year and stratified according to age and sex. The 2004 rate was higher than the 2005 rate for most age and sex groups, though confidence intervals overlapped. The 2006 rates were lower than the 2005 rates for all age groups, and there was no overlap in confidence intervals in men. In conclusion, the introduction of regulations on smoke-free areas was accompanied by a reduction in the AMI hospitalization rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19709517     DOI: 10.1016/s1885-5857(09)72362-x

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  13 in total

1.  [Health, hospitality sector and tobacco industry].

Authors:  Francesc Abella Pons; Rodrigo Córdoba Garcia; Maria Pilar Suárez Bonel
Journal:  Aten Primaria       Date:  2012-01-17       Impact factor: 1.137

2.  [Spanish attitudes to tobacco smoke-free spaces].

Authors:  Rodrigo Córdoba García; Concepción Sanz Andrés
Journal:  Aten Primaria       Date:  2012-06-13       Impact factor: 1.137

3.  The impact of smoke-free laws on asthma discharges: a multistate analysis.

Authors:  Glenn Landers
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

4.  The Spanish smoking law: a model to be followed?

Authors:  María José López
Journal:  Int J Public Health       Date:  2010-06       Impact factor: 3.380

5.  Cardiovascular Events Following Smoke-Free Legislations: An Updated Systematic Review and Meta-Analysis.

Authors:  Miranda R Jones; Joaquin Barnoya; Saverio Stranges; Lia Losonczy; Ana Navas-Acien
Journal:  Curr Environ Health Rep       Date:  2014-09-01

6.  Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis.

Authors:  Crystal E Tan; Stanton A Glantz
Journal:  Circulation       Date:  2012-10-30       Impact factor: 29.690

Review 7.  Legislative smoking bans for reducing harms from secondhand smoke exposure, smoking prevalence and tobacco consumption.

Authors:  Kate Frazer; Joanne E Callinan; Jack McHugh; Susan van Baarsel; Anna Clarke; Kirsten Doherty; Cecily Kelleher
Journal:  Cochrane Database Syst Rev       Date:  2016-02-04

8.  The extension of smoke-free areas and acute myocardial infarction mortality: before and after study.

Authors:  Joan R Villalbí; Emília Sánchez; Josep Benet; Carmen Cabezas; Antonia Castillo; Alex Guarga; Esteve Saltó; Ricard Tresserras
Journal:  BMJ Open       Date:  2011-05-18       Impact factor: 2.692

9.  Reductions in cardiovascular, cerebrovascular, and respiratory mortality following the national irish smoking ban: interrupted time-series analysis.

Authors:  Sericea Stallings-Smith; Ariana Zeka; Pat Goodman; Zubair Kabir; Luke Clancy
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  Impact of a partial smoke-free legislation on myocardial infarction incidence, mortality and case-fatality in a population-based registry: the REGICOR Study.

Authors:  Fernando Agüero; Irene R Dégano; Isaac Subirana; Maria Grau; Alberto Zamora; Joan Sala; Rafel Ramos; Ricard Treserras; Jaume Marrugat; Roberto Elosua
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.